[CrossRef]
68. Omata M, Kanda T, Yu ML, et al. APASL consensus statements
and management algorithms for hepatitis C virus infection. He-
patol Int. 2012; 6(2): 409-5.
[CrossRef]
69. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b the-
rapy in acute hepatitis C: impact of onset of therapy on sustai-
ned virologic response. Gastroenterology. 2006; 130(3): 632-8.
[CrossRef]
70. European Association for the Study of the Liver. EASL Clinical
Practice Guidelines: management of hepatitis C virus infection.
J Hepatol. 2011; 55(2): 245-64.
[CrossRef]
71. Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treat-
ment of acute hepatitis C virus infection. Infect Dis Clin North
Am. 2012; 26(4): 995-1010.
[CrossRef]
72. Ohfuji S, Fukushima W, Tanaka T, et al. Coffee consumption and
reduced risk of hepatocellular carcinoma among patients with
chronic type C liver disease: A case-control study. Hepatology
Res. 2006; 36(3): 201-8.
[CrossRef]
73. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic res-
ponse is durable in patients with chronic hepatitis C treated with
peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;
139(5): 1593-601.
[CrossRef]
74. McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific
Association for the Study of the Liver consensus statements on
the diagnosis, management and treatment of hepatitis C virus in-
fection. J Gastroenterol Hepatol. 2007; 22(5): 615-33.
[CrossRef]
75. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a
plus ribavirin for chronic hepatitis C virus infection. N Engl J
Med. 2002; 347(13): 975-82.
[CrossRef]
76. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-
2b plus ribavirin compared with interferon alfa-2b plus ribavirin for
initial treatment of chronic hepatitis C: a randomised trial. Lancet.
2001; 358(9286): 958-65.
[CrossRef]
77. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment
outcome in patients with chronic hepatitis C: significance of ba-
seline parameters and viral dynamics during therapy. Hepato-
logy. 2003; 37(3): 600-9.
[CrossRef]
78. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Alb-
recht J. Early virologic response to treatment with peginterferon
alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepa-
tology. 2003; 38(3): 645-52.
[CrossRef]
79. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for
previously untreated chronic hepatitis C virus infection. N Engl
J Med. 2011; 364(25): 2405-16.
[CrossRef]
80. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender
Reddy K, Harrison SA, et al. Anemia during treatment with pe-
ginterferon alfa-2b/ribavirin and boceprevir: analysis from the
serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology.
2013; 57(3): 974-84.
[CrossRef]
81. ACIP Adult Immunization Work Group, Bridges CB, Woods L,
Coyne-Beasley T; Centers for Disease Control and Prevention
(CDC). Advisory Committee on Immunization Practices (ACIP)
recommended immunization schedule for adults aged 19 years
and older-United States, 2013. MMWR Surveill Summ. 2013;
62(Suppl. 1):9-19.
82. Shantha S, Thyagarajan SP, Premavathy RK, et al. Correlation of
autoimmune reactivity with hepatitis B and C virus (HBV and
HCV) infection in histologically proven chronic liver diseases. In-
dian J Med Microbiol. 2002; 20(1): 12-5.
83. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between he-
patitis C virus infection and type 2 diabetes mellitus: meta-analy-
sis. World J Gastroenterol. 2012; 18(14): 1642-51.
[CrossRef]
84. Lin CY, Sheen IS, Chen JY, et al. Various predictors of sustained
virologic response in different age groups of patients with genoty-
pe-1 chronic hepatitis C. J Clin Gastroenterol. 2013; 47(9): 794-9.
[CrossRef]
85. Holmberg SD, Lu M, Rupp LB, et al. Noninvasive serum fibro-
sis markers for screening and staging chronic hepatitis C virus
patients in a large US cohort. Clin Infect Dis. 2013; 57(2): 240-6.
[CrossRef]
86. Attallah AM, El-Far M, Omran MM, Farid K, Albannan MS, El-
Dosoky I. Noninvasive diagnosis of liver fibrosis and cirrhosis in
chronic hepatitis C patients. J Clin Lab Anal. 2013; 27(2): 121-9.
[CrossRef]
87. Sporea I, Sirli R, Deleanu A, et al. Comparison of the liver stiff-
ness measurement by transient elastography with the liver bi-
opsy. World J Gastroenterol. 2008; 14(42): 6513-7.
[CrossRef]
88. Goldberg E, Chopra S. Cirrhosis in adults: overview of complica-
tions, general management, and prognosis [İnternet]. Waltham,
MA: UpToDate, Inc. [erişim 2 Haziran 2014]. http://www.uptoda-
te.com/contents/cirrhosis-in-adults-overview-of-complications-
general-management-and-prognosis?source=search_result&se
arch=compensated+cirrhosis&selectedTitle=1~150
89. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral
load and rapid virologic response to peginterferon/ribavirin obvia-
tes a protease inhibitor. Hepatology. 2014; 59(1): 71-7.
[CrossRef]
90. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-
analysis: IL28B polymorphisms predict sustained viral response
in HCV patients treated with pegylated interferon-alpha and ri-
bavirin. Aliment Pharmacol Ther. 2012; 36(2): 91-103.
[CrossRef]
91. Mangia A, Mottola L, Santoro R. Interleukin 28B polymorphisms
as predictor of response in hepatitis C virus genotype 2 and 3
infected patients. World J Gastroenterol. 2013; 19(47): 8924-8.
[CrossRef]
92. Feld JJ. Treatment indication and response to standard of care
with peginterferon and ribavirin in acute and chronic HCV in-
fection. Best Pract Res Clin Gastroenterol. 2012; 26(4): 429-44.
[CrossRef]
93. Niederau C, Mauss S, Boker K, et al. Noncompliance with guide-
lines for the treatment of hepatitis C is frequent in daily practice.
Eur J Gastroenterol Hepatol. 2014; 26(1): 65-73.
[CrossRef]
94. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously
treated chronic HCV genotype 1 infection. N Engl J Med. 2011;
364(13): 1207-17.
[CrossRef]
95. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of
HCV infection. N Engl J Med. 2011; 364(25): 2417-28.
[CrossRef]
96. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B
and spontaneous clearance of hepatitis C virus. Nature. 2009;
461(7265): 798-801.
[CrossRef]
97. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B
predicts hepatitis C treatment-induced viral clearance. Nature.
2009; 461(7262): 399-401.
[CrossRef]
98. Recommendations for Testing Managing, and Treating Hepa-
titis C: Initial Treatment of HCV Infection [İnternet]. Alexandria
and Arlington, VA: American Association for the Study of Liver
Diseases (AASLD) and Infectious Diseases Society of America
Aygen B et al. Kronik Hepatit C Virusu İnfeksiyonunun Yönetimi 37
(IDSA) [erişim 26 Mart 2014]. http://www.hcvguidelines.org/full-
report/initial-treatment-hcv-infection.
99. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) cir-
culates as a population of different but closely related genomes:
quasispecies nature of HCV genome distribution. J Virol. 1992;
66(5): 3225-9.
100. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting
antiviral agents: the best interferon-free combinations. Liver Int.
2014; 34(Suppl. 1): 69-78.
[CrossRef]
101. Vermehren J, Sarrazin C. The role of resistance in HCV treat-
ment. Best Pract Res Clin Gastroenterol. 2012; 26(4): 487-503.
[CrossRef]
102. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-
1a or GT-1b subtype-specific resistance profiles for hepatitis C
virus inhibitors telaprevir and HCV-796. Antimicrob Agents Che-
mother. 2009; 53(5): 2129-32.
[CrossRef]
103. Sayan M. Proteaz inhibitörlerinde Türkiye direnç analizi [DVD].
In: Kronik Hepatit C: Yeni Gelişmeler ve Türkiye Deneyimi (21
Eylül 2013, İstanbul) Atölye Çalışması. İstanbul: Türk Klinik Mik-
robiyoloji ve İnfeksiyon Hastalıkları Derneği, 2013.
104. De Meyer S, Thys K, Dierynck I, Ghys A, Aerssens J, Picchio G.
Deep sequencing screening for telaprevir-resistant viral variants
in previous null responders fails to identify those patients at risk
of failing telaprevir plus peginterferon/ribavirin therapy. J Hepa-
tol. 2012; 56: S465.
[CrossRef]
105. Andonov A, Kadkhoda K, Osiowy C, Kaita K. Pretreatment resis-
tance to hepatitis C virus protease inhibitors boceprevir/telap-
revir in hepatitis C virus subgenotype 1a-infected patients from
Manitoba. Can J Gastroenterol. 2013; 27(7): 414-6.
106. Hoffmann L, Ramos JA, Souza EV, et al. Dynamics of resistan-
ce mutations to NS3 protease inhibitors in a cohort of Brazilian
patients chronically infected with hepatitis C virus (genotype 1)
treated with pegylated interferon and ribavirin: a prospective
longitudinal study. Virol J. 2013; 10: 57.
[CrossRef]
107. Palanisamy N, Danielsson A, Kokkula C, et al. Implications of ba-
seline polymorphisms for potential resistance to NS3 protease
inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral
Res. 2013; 99(1): 12-7.
[CrossRef]
108. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically
targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimic-
rob Chemother. 2010; 65(2): 202-12.
[CrossRef]
109. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated
interferon-alpha-2a inhibit wild-type and resistant genotype 1 he-
patitis C virus replication in patients. Hepatology. 2007; 46(3): 631-9.
[CrossRef]
110. Kieffer TL, De Meyer S, Bartels DJ, et al. Hepatitis C viral evolu-
tion in genotype 1 treatment-naive and treatment-experienced
patients receiving telaprevir-based therapy in clinical trials. PloS
One. 2012; 7(4): e34372.
[CrossRef]
111. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict
response of patients with hepatitis C virus infection to bocepre-
vir. Gastroenterology. 2012; 143(3): 608-18 e1-5.
112. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B
polymorphism improves viral kinetics and is the strongest pret-
reatment predictor of sustained virologic response in genotype
1 hepatitis C virus. Gastroenterology. 2010; 139(1): 120-9 e18.
113. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alp-
ha2a and ribavirin combination therapy in chronic hepatitis C: a
randomized study of treatment duration and ribavirin dose. Ann
Intern Med. 2004; 140(5): 346-55.
[CrossRef]
114. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of
HCV genotype 1 patients responding to 24 weeks peginterferon
alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43(5): 954-60.
[CrossRef]
115. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and
ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with
rapid virological response. Gastroenterology. 2008; 135(2): 451-8.
[CrossRef]
116. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment
with peginterferon alfa-2b plus ribavirin in patients with chronic
hepatitis C infected with genotype 1 and low pretreatment vire-
mia. J Hepatol. 2006; 44(1): 97-103.
[CrossRef]
117. Mangia A, Minerva N, Bacca D, et al. Individualized treatment
duration for hepatitis C genotype 1 patients: a randomized cont-
rolled trial. Hepatology. 2008; 47(1): 43-50.
[CrossRef]
118. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathu-
rin P. Shortened treatment duration in treatment-naive genotype
1 HCV patients with rapid virological response: a meta-analysis.
J Hepatol. 2010; 52(1): 25-31.
[CrossRef]
119. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sus-
tained virologic response in hepatitis B and C. J Hepatol. 2008;
49(4): 634-51.
[CrossRef]
120. Wartelle-Bladou C, Le Folgoc G, Bourliere M, Lecomte L. Hepati-
tis C therapy in non-genotype 1 patients: the near future. J Viral
Hepat. 2012; 19(8): 525-36.
[CrossRef]
121. Sung H, Chang M, Saab S. Management of hepatitis C anti-
viral therapy adverse effects. Curr Hepat Rep. 2011; 10(1):
33-40.
[CrossRef]
122. Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J. Thyroid
function and changes in ultrasound morphology during antivi-
ral therapy with pegylated interferon and ribavirin in patients
with chronic hepatitis C. J Viral Hepat. 2009; 16(3): 168-77.
[CrossRef]
123. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-
induced haemolytic anaemia in patients with chronic hepatitis
C. Aliment Pharmacol Ther. 2002; 16(9): 1623-32.
[CrossRef]
124. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previo-
usly treated chronic HCV infection. N Engl J Med. 2010; 362(14):
1292-303.
[CrossRef]
125. Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related
dermatitis. JAMA Dermatol. 2013; 149(2): 152-8.
[CrossRef]
126. Hofmann WP, Chung TL, Osbahr C, et al. Impact of ribavirin on
HCV replicon RNA decline during treatment with interferon-alp-
ha and the protease inhibitors boceprevir or telaprevir. Antivir
Ther. 2011; 16(5): 695-704.
127. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untre-
ated chronic HCV genotype 1 infection. N Engl J Med. 2011;
364(13): 1195-206.
[CrossRef]
128. Koff RS. Review article: the efficacy and safety of sofosbuvir, a
novel, oral nucleotide NS5B polymerase inhibitor, in the treat-
ment of chronic hepatitis C virus infection. Aliment Pharmacol
Ther. 2014; 39(5): 478-87.
[CrossRef]
129. Dienstag JL. Chronic viral hepatitis. In: Mandell GL, Bennett JE,
Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and
Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churc-
hill Livingstone Elsevier, 2010: 1593-617.
[CrossRef]
130. Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients
with chronic hepatitis C receiving a combined therapy of interfe-
ron and ribavirin: incidence, associated factors and prognosis. J
Gastroenterol Hepatol. 2006; 21(1 Pt. 2): 319-26.
[CrossRef]
131. Aygen B. Kronik hepatit C’de tedavi ve izlem. In: Köksal İ, Leb-
lebicioğlu H, eds. Kronik Hepatitlerin Tedavisinde Güncel Yakla-
şımlar. Ankara: Bilimsel Tıp Yayınevi, 2007: 173-83.
132. Recommendations for Testing Managing, and Treating Hepatitis
C: Retreatment of Persons In Whom Prior Therapy Has Failed
[İnternet]. Alexandria and Arlington, VA: American Association
for the Study of Liver Diseases (AASLD) and Infectious Diseases
Society of America (IDSA) [erişim 18 Şubat 2014]. http://www.
38
Klimik Dergisi 2014; 27(Özel Sayı 1): 19-39
hcvguidelines.org/full-report/retreatment-persons-whom-prior-
therapy-has-failed.
133. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, mana-
gement, and treatment of hepatitis C. Hepatology. 2004; 39(4):
1147-71.
[CrossRef]
134. Corey KE, Servoss JC, Casson DR, et al. Pilot study of postex-
posure prophylaxis for hepatitis C virus in healthcare workers.
Infect Control Hosp Epidemiol. 2009; 30(10): 1000-5.
[CrossRef]
135. Aygen B. Yoğun bakım biriminde çalışanlarda kan ve vücut sıvı-
ları ile bulaşan infeksiyonlardan korunma. In: Akalın H, Aygen B,
Yalçın AN, eds. İnfeksiyon Hastalıklarında Güncel Durum. İstan-
bul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği
Yayınları, 2009: 141-51.
136. Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yaz-
danpanah Y. Costs and cost-effectiveness of different follow-up
schedules for detection of occupational hepatitis C virus infecti-
on. Gut. 2009; 58(1): 105-10.
[CrossRef]
137. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C.
Sensitivity and specificity of third-generation hepatitis C virus
antibody detection assays: an analysis of the literature. J Viral
Hepat. 2001; 8(2): 87-95.
[CrossRef]
138. Lavanchy D, Steinmann J, Moritz A, Frei PC. Evaluation of a new
automated third-generation anti-HCV enzyme immunoassay. J
Clin Lab Anal. 1996; 10(5): 269-76.
3.0.CO;2-3">[CrossRef]
139. Lefrere JJ, Roudot-Thoraval F, Lunel F, et al. Expertise of French la-
boratories in detection, genotyping, and quantification of hepatitis
C virus RNA in serum. J Clin Microbiol. 2004; 42(5): 2027-30.
[Cross-
Ref]
140. Updated U.S. Public Health Service Guidelines for the Mana-
gement of Occupational Exposures to HBV, HCV, and HIV and
Recommendations for Postexposure Prophylaxis. MMWR Re-
comm Rep. 2001; 50(RR-11): 1-52.
141. Puro V, De Carli G, Cicalini S, et al. European recommendations
for the management of healthcare workers occupationally expo-
sed to hepatitis B virus and hepatitis C virus. Euro Surveill. 2005;
10(10): 260-4.
142. Deuffic-Burban S, Delarocque-Astagneau E, Abiteboul D, Bouvet
E, Yazdanpanah Y. Blood-borne viruses in health care workers:
prevention and management. J Clin Virol. 2011; 52(1): 4-10.
[CrossRef]
143. Ramsay ME. Guidance on the investigation and management of
occupational exposure to hepatitis C. PHLS Advisory Committee
on Blood Borne Viruses. Commun Dis Public Health. 1999; 2(4):
258-62.
144. Charles PG, Angus PW, Sasadeusz JJ, Grayson ML. Manage-
ment of healthcare workers after occupational exposure to he-
patitis C virus. Med J Aust. 2003; 179(3): 153-7.
Aygen B et al. Kronik Hepatit C Virusu İnfeksiyonunun Yönetimi 39
Dostları ilə paylaş: |